Report cover image

Knee Osteoarthritis Drugs Market Growth, Size, Trends Analysis - By Drug Type, By Route of Administration, By Age Group - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Publisher SPER Market Research Pvt. Ltd.
Published Oct 13, 2025
Length 258 Pages
SKU # SPER20565938

Description

Knee Osteoarthritis Drugs Market Introduction and Overview

According to SPER market research, ‘Global Knee Osteoarthritis Drugs Market Size- By Drug Type, By Route of Administration, By Age Group- Regional Outlook, Competitive Strategies and Segment Forecast to 2034’ states that the Global Knee Osteoarthritis Drugs Market is predicted to reach 15.3 billion by 2034 with a CAGR of 8.24%.

The degeneration of cartilage in osteoarthritis of the knee results in pain, stiffness, swelling, and restricted knee mobility. It is usually more common in older adults, but it can also strike younger people due to trauma, obesity, or genetic predisposition. The illness may have a significant impact on daily activities and lives. Treatment primarily aims to control symptoms and slow the progression of the illness through the use of medications such as analgesics, corticosteroids, nonsteroidal anti-inflammatory drugs, and new disease-modifying therapies.

Restraints:

There are several challenges facing the knee osteoarthritis drug market that could limit its growth. High treatment costs, particularly for injectables and advanced therapies, may make treatment inaccessible to patients. Side effects and safety concerns associated with long-term use of corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and certain analgesics may reduce patient adherence. When existing treatments fail to halt the progression of their diseases, some patients resort to surgery.

Scope of the report:

Report Metric Details
Market size available for years 2021-2034
Base year considered 2024
Forecast period 2025-2034

Segments covered By

Drug Type, By Route of Administration, By Age Group

Regions covered

North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa

Companies Covered

Anika Therapeutics, Avanos, Biotech Healthcare, Bioventus, Ferring Pharmaceuticals, Fidia Pharma, GlaxoSmithKline (GSK), Haleon, Kenvue, Organon LLC, Pacira Pharmaceuticals, Pfizer, Premier Surgical, Sanofi, Stellar Pharmaceuticals.

Global Knee Osteoarthritis Drugs Market Segmentation:

By Drug Type: Based on the Drug type, Global Knee Osteoarthritis Drugs Market is segmented as: Non-steroidal anti-inflammatory drugs (NSAIDs), Corticosteroids, Viscosupplementation, Analgesics, Other drug types.

By Route of Administration: Based on the Route of Administration, Global Knee Osteoarthritis Drugs Market is segmented as; Oral, Parenteral, Topical

By Age Group: Based on the Age Group, Global Knee Osteoarthritis Drugs Market is segmented as; 18 – 44,45 –64, and Above 65.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Table of Contents

258 Pages
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPERs internal database
2.1.4. Premium insight from KOLs
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTERs Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Knee Osteoarthritis Drugs Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Knee Osteoarthritis Drugs Market
7. Global Knee Osteoarthritis Drugs Market, By Drug Type (USD Million) 2021-2034
7.1. Non-steroidal anti-inflammatory drugs (NSAIDs)
7.2. Corticosteroids
7.3. Viscosupplementation
7.4. Analgesics
7.5. Other drug types
8. Global Knee Osteoarthritis Drugs Market, By Route of Administration (USD Million) 2021-2034
8.1. Oral
8.2. Parenteral
8.3. Topical
9. Global Knee Osteoarthritis Drugs Market, By Age Group (USD Million) 2021-2034
9.1. 18 - 44
9.2. 45 - 64
9.3. Above 65
10. Global Knee Osteoarthritis Drugs Market, (USD Million) 2021-2034
10.1. Global Knee Osteoarthritis Drugs Market Size and Market Share
11. Global Knee Osteoarthritis Drugs Market, By Region, (USD Million) 2021-2034
11.1. Asia-Pacific
11.1.1. Australia
11.1.2. China
11.1.3. India
11.1.4. Japan
11.1.5. South Korea
11.1.6. Rest of Asia-Pacific
11.2. Europe
11.2.1. France
11.2.2. Germany
11.2.3. Italy
11.2.4. Spain
11.2.5. United Kingdom
11.2.6. Rest of Europe
11.3. Middle East and Africa
11.3.1. Kingdom of Saudi Arabia
11.3.2. United Arab Emirates
11.3.3. Qatar
11.3.4. South Africa
11.3.5. Egypt
11.3.6. Morocco
11.3.7. Nigeria
11.3.8. Rest of Middle-East and Africa
11.4. North America
11.4.1. Canada
11.4.2. Mexico
11.4.3. United States
11.5. Latin America
11.5.1. Argentina
11.5.2. Brazil
11.5.3. Rest of Latin America
12. Company Profile
12.1. Anika Therapeutics
12.1.1. Company details
12.1.2. Financial outlook
12.1.3. Product summary
12.1.4. Recent developments
12.2. Avanos
12.2.1. Company details
12.2.2. Financial outlook
12.2.3. Product summary
12.2.4. Recent developments
12.3. Biotech Healthcare
12.3.1. Company details
12.3.2. Financial outlook
12.3.3. Product summary
12.3.4. Recent developments
12.4. Bioventus
12.4.1. Company details
12.4.2. Financial outlook
12.4.3. Product summary
12.4.4. Recent developments
12.5. Ferring Pharmaceuticals
12.5.1. Company details
12.5.2. Financial outlook
12.5.3. Product summary
12.5.4. Recent developments
12.6. Fidia Pharma
12.6.1. Company details
12.6.2. Financial outlook
12.6.3. Product summary
12.6.4. Recent developments
12.7. GlaxoSmithKline
12.7.1. Company details
12.7.2. Financial outlook
12.7.3. Product summary
12.7.4. Recent developments
12.8. Haleon
12.8.1. Company details
12.8.2. Financial outlook
12.8.3. Product summary
12.8.4. Recent developments
12.9. Kenvue
12.9.1. Company details
12.9.2. Financial outlook
12.9.3. Product summary
12.9.4. Recent developments
12.10. Organon LLC
12.10.1. Company details
12.10.2. Financial outlook
12.10.3. Product summary
12.10.4. Recent developments
12.11. Pacira Pharmaceuticals
12.11.1. Company details
12.11.2. Financial outlook
12.11.3. Product summary
12.11.4. Recent developments
12.12. Pfizer
12.12.1. Company details
12.12.2. Financial outlook
12.12.3. Product summary
12.12.4. Recent developments
12.13. Premier Surgical
12.13.1. Company details
12.13.2. Financial outlook
12.13.3. Product summary
12.13.4. Recent developments
12.14. Sanofi
12.14.1. Company details
12.14.2. Financial outlook
12.14.3. Product summary
12.14.4. Recent developments
12.15. Stellar Pharmaceuticals
12.15.1. Company details
12.15.2. Financial outlook
12.15.3. Product summary
12.15.4. Recent developments
12.16. Others
13. Conclusion
14. List of Abbreviations
15. Reference Links

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us